ZYMEZymeworks Inc.
$25.80+59% 1Y
$25.80
$16.1652 weeks$31.05
The financials
Zymeworks Inc. by the numbers
Zymeworks Inc. (ZYME) reported revenue of $4.6M in Q2 2026 (quarter ended Jun 30, 2026), down 91% from the same quarter a year earlier. That came with net loss of $45M. For the full year FY2025, revenue was $106M (+39% year on year) and net income −$81M. Its largest product in Q2 2026 was Royalty at $1.6M, 59% of the disclosed total, well ahead of Drug Supply For Ongoing Studies at 29%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $4.6M | $49M | −91% |
| Operating income | −$42M | −$674K | n/a |
| Net income | −$45M | $2.3M | to a loss |
| Diluted EPS | −$0.62 | $0.03 | to a loss |
| Product | Revenue | Share |
|---|---|---|
| Royalty | $1.6M | 59% |
| Drug Supply For Ongoing Studies | $791K | 29% |
| Research Support Payments And Other Service | $291K | 11% |
| Drug Supply | $45K | 1.7% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $2.7M (+24%)
Royalty grew +189% year on yearRecognition Of Deferred -100% year on year
Segment Latestquarter on quarteryear on year
- Royalty$1.6M$1.6Mquarter on quarter +19%year on year +189%+19%+189%
- Drug Supply For Ongoing Studies$791.0K$791.0Kquarter on quarter +129%year on year -57%+129%-57%
- Research Support Payments And Other Service$291.0K$291.0Kquarter on quarter -26%year on year -39%-26%-39%
- Drug Supply$45.0K$45.0Kquarter on quarter -62%year on year n/a-62%n/a
- Milestone$0.00$0.00quarter on quarter n/ayear on year -100%n/a-100%
- Option Exercise Fee$0.00$0.00quarter on quarter n/ayear on year -100%n/a-100%
- Recognition Of Deferred$0.00$0.00quarter on quarter n/ayear on year -100%n/a-100%